Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDSeres Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 2 | -$0.13 | $0.31 | $0.10 |
| Q2 2025 | 2 | -$2.85 | -$2.13 | -$2.49 |
| Q3 2025 | 1 | $0.27 | $0.55 | $0.46 |
| Q4 2025 | 1 | -$2.19 | -$2.14 | -$2.17 |
| Q1 2026 | 1 | -$2.00 | -$2.00 | -$2.00 |
| Q2 2026 | 1 | -$2.07 | -$2.07 | -$2.07 |
| Q3 2026 | 1 | -$2.06 | -$2.06 | -$2.06 |
| Q4 2026 | 1 | -$2.12 | -$2.12 | -$2.12 |
Seres Therapeutics, Inc. Earnings Date And Information
Seres Therapeutics, Inc. last posted its earnings results on Wednesday, November 5th, 2025. The company reported $0.94 earnings per share for the quarter, topping analysts' consensus estimates of $0.05 by $0.89. The company had revenue of 351.00 K for the quarter and had revenue of 0 for the year. Seres Therapeutics, Inc. has generated $-19 earnings per share over the last year ($-18.8636 diluted earnings per share) and currently has a price-to-earnings ratio of 29.07. Seres Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 5th, 2025 based on prior year's report dates.
Seres Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/05/2025 | Q3 2025 | $0.05 | $0.94 | 0.89 | $7.83 M | $351.00 K |
| 08/06/2025 | Q2 2025 | -$2.72 | -$2.27 | 0.45 | $6.25 M | $0 |
| 05/07/2025 | Q1 2025 | -$0.67 | $3.76 | 4.43 | N/A | $0 |
| 03/13/2025 | Q4 2024 | -$0.17 | -$1.81 | -1.64 | N/A | $0 |
| 11/13/2024 | Q3 2024 | -$5.00 | -$7.59 | -2.59 | $31.00 M | $0 |
| 08/13/2024 | Q2 2024 | -$5.60 | -$4.34 | 1.26 | $-263,833 | $0 |
| 05/08/2024 | Q1 2024 | -$7.20 | -$5.49 | 1.71 | N/A | $0 |
| 03/05/2024 | Q4 2023 | -$8.00 | -$6.38 | 1.62 | N/A | $64.00 K |
| 11/02/2023 | Q3 2023 | -$9.40 | -$7.46 | 1.94 | $1.50 M | $0 |
| 08/08/2023 | Q2 2023 | $11.00 | $7.29 | -3.71 | $125.67 M | $126.47 M |
| 05/09/2023 | Q1 2023 | -$11.40 | -$11.31 | 0.09 | $1.58 M | $-522,000 |
| 03/07/2023 | Q4 2022 | -$8.20 | -$10.99 | -2.79 | $6.00 M | $975.00 K |
| 11/02/2022 | Q3 2022 | -$9.00 | -$9.79 | -0.79 | $7.00 M | $3.44 M |
| 08/03/2022 | Q2 2022 | -$11.60 | -$14.03 | -2.43 | $4.54 M | $1.22 M |
| 05/04/2022 | Q1 2022 | -$11.20 | -$12.29 | -1.09 | $8.49 M | $1.49 M |
| 03/01/2022 | Q4 2021 | -$9.00 | -$10.88 | -1.88 | $12.25 M | $7.22 M |
| 11/10/2021 | Q3 2021 | -$9.40 | $14.87 | 24.27 | $28.52 M | $126.73 M |
| 08/03/2021 | Q2 2021 | -$8.20 | -$10.55 | -2.35 | $5.86 M | $5.26 M |
| 05/04/2021 | Q1 2021 | -$6.60 | -$7.75 | -1.15 | $6.45 M | $5.72 M |
| 03/02/2021 | Q4 2020 | -$5.20 | -$3.99 | 1.21 | $6.06 M | $17.56 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Seres Therapeutics, Inc. Earnings: FAQ's
Seres Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 5th, 2025 based offlast year's report dates.
In the previous quarter, Seres Therapeutics, Inc. (:MCRB) reported $0.94 earnings per share (EPS) to beat the analysts' consensus estimate of $0.05 by $0.89.
The conference call for Seres Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Seres Therapeutics, Inc.'s latest earnings report can be read online.
Seres Therapeutics, Inc. (:MCRB) has a recorded net income of $136.00 K.Seres Therapeutics, Inc. has generated $-18.8636 earnings per share over the last four quarters.
Seres Therapeutics, Inc. (:MCRB) has a price-to-earnings ratio of 29.07 and price/earnings-to-growth ratio is -0.31.